ReproCELL: Notice Concerning Decrease in Capital Reserve Amount and Disposal of Surplus Funds
ReproCELL: Notice regarding transfer of certified public accountants, etc.
ReproCELL: Notice regarding subsidies to consolidated subsidiaries (REPROCELL USA Inc.)
ReproCELL: Notice regarding the monthly exercise status of the 16th Stock Acquisition Rights (with exercise price amendment clauses and exercise permission clauses)
ReproCELL: Partial correction to “Notice of patent registration in Japan relating to treatment of polyglutamine disease by Steminent”
ReproCELL: Notice of patent registration in Japan relating to treatment of polyglutamine disease by Steminent
ReproCELL: Notice regarding adoption of the AMED public offering project “Basic Technology Development Project for Industrialization of Regenerative Medicine and Gene Therapy”
Reprocel: Notice regarding the monthly exercise status of the 16th Stock Acquisition Rights (with exercise price amendment clauses and exercise permission clauses)
Reprocel: Notice regarding listing of the investor Stemminent on the Taiwan Emerging Stock Board
Reprocel: Notice regarding the monthly exercise status of the 16th Stock Acquisition Rights (with exercise price amendment clauses and exercise permission clauses)
ReproCELL: Notice Concerning Mass Exercise of the 16th Stock Acquisition Rights (with Exercise Price Amendment Clauses and Exercise Permit Clauses)
ReproCELL: Notice regarding a decrease in non-operating income (foreign exchange profit)
ReproCELL: Notice of new pipeline decision for tumor-infiltrating lymphocyte infusion therapy (TIL therapy)
ReproCELL: Notice regarding the monthly exercise status of the 16th Stock Acquisition Rights (with exercise price amendment clauses and exercise permission clauses)
ReproCELL: Notice Concerning Mass Exercise of the 16th Stock Acquisition Rights (with Exercise Price Amendment Clauses and Exercise Permit Clauses)
ReproCELL: Notice of conclusion of a domestic sales agency agreement with Interscience
ReproCELL: Notice of commencement of new business related to human iPS cell-derived mesenchymal stem cells
ReproCELL: Announcement of the conclusion of a sales agency agreement (exclusive sale in Japan) with Cercolabs and the commencement of sales of mesenchymal stem cells and cell secretions for research and clinical use
ReproCELL: Notice of patent registration in Japan relating to Steminent's polyglutamine disease treatment composition
ReproCELL: Notice of conclusion of basic sales agreement with Nippi and commencement of sales of MatriMix (511)
No Data